New directions in the systemic treatment of metastatic thyroid cancer

Michaela J. Higgins, Arlene A. Forastiere, Shanthi Marur

Research output: Contribution to journalArticle

Abstract

Medical oncologists have traditionally had little to offer patients with metastatic radioactive iodineresistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid cancer is less than 50%, with little response obtained from standard cytotoxic chemotherapies. In recent years, however, huge advances have been made in understanding the molecular pathways and cellular pathogenesis of this disease. This knowledge has in turn led to the development of a range of targeted therapies, some specific to thyroid cancer genetic alterations such as the RET/PTC translocation, and others that exploit general malignant properties such as angiogenesis. This review highlights novel targeted agents for the treatment of differentiated and medullary thyroid cancers being studied at this time, and the results of recently published trials. We propose that such patients should be managed, whenever possible, within a clinical trial, in order to access the most promising new drugs for thyroid cancer. In cases where trials are unavailable, we recommend off-label use of the currently available oral multikinase inhibitors such as sorafenib and sunitinib rather than traditional chemotherapies.

Original languageEnglish (US)
JournalOncology
Volume23
Issue number9
StatePublished - Aug 2009

Fingerprint

Thyroid Neoplasms
Off-Label Use
Drug Therapy
Factor IX
Therapeutics
Survival Rate
Clinical Trials
Direction compound
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New directions in the systemic treatment of metastatic thyroid cancer. / Higgins, Michaela J.; Forastiere, Arlene A.; Marur, Shanthi.

In: Oncology, Vol. 23, No. 9, 08.2009.

Research output: Contribution to journalArticle

Higgins, Michaela J. ; Forastiere, Arlene A. ; Marur, Shanthi. / New directions in the systemic treatment of metastatic thyroid cancer. In: Oncology. 2009 ; Vol. 23, No. 9.
@article{0769da09796b495e966a9f76880ee82b,
title = "New directions in the systemic treatment of metastatic thyroid cancer",
abstract = "Medical oncologists have traditionally had little to offer patients with metastatic radioactive iodineresistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid cancer is less than 50{\%}, with little response obtained from standard cytotoxic chemotherapies. In recent years, however, huge advances have been made in understanding the molecular pathways and cellular pathogenesis of this disease. This knowledge has in turn led to the development of a range of targeted therapies, some specific to thyroid cancer genetic alterations such as the RET/PTC translocation, and others that exploit general malignant properties such as angiogenesis. This review highlights novel targeted agents for the treatment of differentiated and medullary thyroid cancers being studied at this time, and the results of recently published trials. We propose that such patients should be managed, whenever possible, within a clinical trial, in order to access the most promising new drugs for thyroid cancer. In cases where trials are unavailable, we recommend off-label use of the currently available oral multikinase inhibitors such as sorafenib and sunitinib rather than traditional chemotherapies.",
author = "Higgins, {Michaela J.} and Forastiere, {Arlene A.} and Shanthi Marur",
year = "2009",
month = "8",
language = "English (US)",
volume = "23",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9",

}

TY - JOUR

T1 - New directions in the systemic treatment of metastatic thyroid cancer

AU - Higgins, Michaela J.

AU - Forastiere, Arlene A.

AU - Marur, Shanthi

PY - 2009/8

Y1 - 2009/8

N2 - Medical oncologists have traditionally had little to offer patients with metastatic radioactive iodineresistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid cancer is less than 50%, with little response obtained from standard cytotoxic chemotherapies. In recent years, however, huge advances have been made in understanding the molecular pathways and cellular pathogenesis of this disease. This knowledge has in turn led to the development of a range of targeted therapies, some specific to thyroid cancer genetic alterations such as the RET/PTC translocation, and others that exploit general malignant properties such as angiogenesis. This review highlights novel targeted agents for the treatment of differentiated and medullary thyroid cancers being studied at this time, and the results of recently published trials. We propose that such patients should be managed, whenever possible, within a clinical trial, in order to access the most promising new drugs for thyroid cancer. In cases where trials are unavailable, we recommend off-label use of the currently available oral multikinase inhibitors such as sorafenib and sunitinib rather than traditional chemotherapies.

AB - Medical oncologists have traditionally had little to offer patients with metastatic radioactive iodineresistant thyroid cancer. The 3-year survival rate of patients with differentiated thyroid cancer is less than 50%, with little response obtained from standard cytotoxic chemotherapies. In recent years, however, huge advances have been made in understanding the molecular pathways and cellular pathogenesis of this disease. This knowledge has in turn led to the development of a range of targeted therapies, some specific to thyroid cancer genetic alterations such as the RET/PTC translocation, and others that exploit general malignant properties such as angiogenesis. This review highlights novel targeted agents for the treatment of differentiated and medullary thyroid cancers being studied at this time, and the results of recently published trials. We propose that such patients should be managed, whenever possible, within a clinical trial, in order to access the most promising new drugs for thyroid cancer. In cases where trials are unavailable, we recommend off-label use of the currently available oral multikinase inhibitors such as sorafenib and sunitinib rather than traditional chemotherapies.

UR - http://www.scopus.com/inward/record.url?scp=70349271352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349271352&partnerID=8YFLogxK

M3 - Article

C2 - 19777762

AN - SCOPUS:70349271352

VL - 23

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9

ER -